BioMark Diagnostics Inc. (BMKDF)
USD 0.15
(0.0%)
USD 0.15
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -919.04 Thousand CAD | 31.71% |
| 2023 | -1.34 Million CAD | -10.0% |
| 2022 | -1.22 Million CAD | -14.46% |
| 2021 | -1.02 Million CAD | 10.24% |
| 2020 | -1.19 Million CAD | -118.25% |
| 2019 | -545.61 Thousand CAD | 24.92% |
| 2018 | -726.74 Thousand CAD | -0.02% |
| 2017 | -715.42 Thousand CAD | 48.54% |
| 2016 | -1.41 Million CAD | 51.2% |
| 2015 | -2.89 Million CAD | 0.0% |
| 2014 | - CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -331.86 Thousand CAD | 10.08% |
| 2024 Q2 | -343.78 Thousand CAD | -3.59% |
| 2024 Q3 | -341.5 Thousand CAD | 0.66% |
| 2024 FY | - CAD | -5.03% |
| 2024 Q4 | -396.39 Thousand CAD | -16.07% |
| 2023 Q1 | -294.28 Thousand CAD | 47.7% |
| 2023 Q4 | -369.07 Thousand CAD | -31.26% |
| 2023 Q2 | -401.27 Thousand CAD | -36.35% |
| 2023 Q3 | -281.16 Thousand CAD | 29.93% |
| 2023 FY | - CAD | -10.0% |
| 2022 FY | - CAD | -14.46% |
| 2022 Q4 | -562.69 Thousand CAD | -177.99% |
| 2022 Q3 | -202.41 Thousand CAD | -15.44% |
| 2022 Q2 | -175.33 Thousand CAD | 38.05% |
| 2022 Q1 | -283.03 Thousand CAD | 49.49% |
| 2021 Q4 | -560.4 Thousand CAD | -190.07% |
| 2021 FY | - CAD | 10.24% |
| 2021 Q1 | -130.82 Thousand CAD | 53.22% |
| 2021 Q3 | -193.19 Thousand CAD | -4.73% |
| 2021 Q2 | -184.47 Thousand CAD | -41.01% |
| 2020 Q1 | -120.55 Thousand CAD | 2.16% |
| 2020 Q4 | -279.67 Thousand CAD | 58.44% |
| 2020 Q2 | -135.92 Thousand CAD | -12.75% |
| 2020 FY | - CAD | -118.25% |
| 2020 Q3 | -672.89 Thousand CAD | -395.04% |
| 2019 Q3 | -168.66 Thousand CAD | -5.05% |
| 2019 FY | - CAD | 24.92% |
| 2019 Q4 | -123.21 Thousand CAD | 26.95% |
| 2019 Q2 | -160.55 Thousand CAD | -44.76% |
| 2019 Q1 | -110.91 Thousand CAD | 21.83% |
| 2018 Q2 | -218.42 Thousand CAD | -11.6% |
| 2018 Q3 | -176.37 Thousand CAD | 19.25% |
| 2018 Q4 | -141.88 Thousand CAD | 19.56% |
| 2018 FY | - CAD | -0.02% |
| 2018 Q1 | -195.72 Thousand CAD | 19.59% |
| 2017 Q3 | -111.75 Thousand CAD | 25.65% |
| 2017 FY | - CAD | 48.54% |
| 2017 Q4 | -243.4 Thousand CAD | -117.8% |
| 2017 Q2 | -150.3 Thousand CAD | 30.26% |
| 2017 Q1 | -215.53 Thousand CAD | 69.43% |
| 2016 Q3 | -260.89 Thousand CAD | -12.36% |
| 2016 Q2 | -232.18 Thousand CAD | -10.94% |
| 2016 Q1 | -209.29 Thousand CAD | 70.74% |
| 2016 Q4 | -705.15 Thousand CAD | -170.29% |
| 2016 FY | - CAD | 51.2% |
| 2015 Q1 | -65.99 Thousand CAD | 0.0% |
| 2015 Q2 | -51.4 Thousand CAD | 22.11% |
| 2015 Q3 | -2.05 Million CAD | -3889.1% |
| 2015 Q4 | -715.31 Thousand CAD | 65.12% |
| 2015 FY | - CAD | 0.0% |
| 2014 FY | - CAD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| American Bio Medica Corporation | -1.16 Million USD | 20.976% |
| Arrayit Corporation | -3.07 Million USD | 70.137% |
| Atlantic International Corp. | -5.38 Million USD | 82.948% |
| Biocept, Inc. | -30.24 Million USD | 96.961% |
| Bioqual, Inc. | 3.03 Million USD | 130.309% |
| CardioGenics Holdings Inc | -757.37 Thousand USD | -21.346% |
| DermTech, Inc. | -97.89 Million USD | 99.061% |
| Global WholeHealth Partners Corporation | - USD | Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 2.91 Billion USD | 100.032% |
| HTG Molecular Diagnostics, Inc. | -20.24 Million USD | 95.46% |
| iMD Companies, Inc. | -154.65 Thousand USD | -494.241% |
| IDenta Corp. | 71.58 Thousand USD | 1383.818% |
| Interpace Biosciences, Inc. | 3.83 Million USD | 123.952% |
| Integrative Health Technologies, Inc. | 38.69 Thousand USD | 2475.412% |
| InVitro International | 6680.00 USD | 13858.189% |
| Lumos Diagnostics Holdings Limited | -5.43 Million USD | 83.093% |
| Many Bright Ideas Technologies Inc. | -12.13 Thousand USD | -7474.147% |
| Medical Imaging Corp. | -896.74 Thousand USD | -2.487% |
| NovelStem International Corp. | -3.78 Million USD | 75.724% |
| Optigenex Inc. | -1.18 Million USD | 22.556% |
| PharmChem, Inc. | 1.05 Million USD | 187.212% |
| Proteome Sciences plc | -1.13 Million USD | 19.169% |
| Response Genetics, Inc | -19.66 Million USD | 95.327% |
| Rennova Health, Inc. | -234.81 Thousand USD | -291.392% |
| RushNet, Inc. | -614.85 Thousand USD | -49.475% |
| ScreenPro Security Inc. | -3.43 Million USD | 73.244% |
| Stella Diagnostics Inc. | -5.7 Million USD | 83.897% |
| StageZero Life Sciences Ltd. | -10.27 Million USD | 91.051% |
| Todos Medical Ltd. | -9.39 Million USD | 90.217% |